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Abstract
Background: Gene therapy mediated by synthetic vectors may provide opportunities for new treatments for cystic fibrosis
(CF) via aerosolisation. Vectors for CF must transfect the airway epithelium efficiently and not cause inflammation so they
are suitable for repeated dosing. The inhaled aerosol should be deposited in the airways since the cystic fibrosis
transmembrane conductance regulator gene (CFTR) is expressed predominantly in the epithelium of the submucosal glands
and in the surface airway epithelium. The aim of this project was to develop an optimised aerosol delivery approach
applicable to treatment of CF lung disease by gene therapy.
Methodology: The vector suspension investigated in this study comprises receptor-targeting peptides, cationic liposomes
and plasmid DNA that self-assemble by electrostatic interactions to form a receptor-targeted nanocomplex (RTN) of
approximately 150 nm with a cationic surface charge of +50 mV. The aerodynamic properties of aerosolised nanocomplexes
produced with three different nebulisers were compared by determining aerosol deposition in the different stages of a Next
Generation Pharmaceutical Impactor (NGI). We also investigated the yield of intact plasmid DNA by agarose gel
electrophoresis and densitometry, and transfection efficacies in vitro and in vivo.
Results: RTNs nebulised with the AeroEclipse II BAN were the most effective, compared to other nebulisers tested, for gene
delivery both in vitro and in vivo. The biophysical properties of the nanocomplexes were unchanged after nebulisation while
the deposition of RTNs suggested a range of aerosol aerodynamic sizes between 5.5 mm–1.4 mm cut off (NGI stages 3–6)
compatible with deposition in the central and lower airways.
Conclusions: RTNs showed their ability at delivering genes via nebulisation, thus suggesting their potential applications for
therapeutic interventions of cystic fibrosis and other respiratory disorders.
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Introduction
Cystic fibrosis (CF) is one of the most common autosomal
recessively inherited disorders with a carrier frequency of 5% in
the Caucasian population [1,2]. CF predominantly affects the
exocrine epithelium in a number of secretory tissues and organs.
Respiratory insufficiency is the major cause of CF mortality. The
defect is caused by mutations in the gene for the cystic fibrosis
transmembrane conductance regulator (CFTR) [3,4], which is a
cAMP-activated chloride channel in the apical membrane
of the surface epithelium (for review see [5]). The mutated CFTR
causes an ion imbalance leading to a reduced volume of the
airway surface liquid, mucus dehydration and reduced muco-
ciliary clearance [6]. This provides a favourable environment for
bacterial infections leading to a progressive decline of lung
function [7].
The aim of CF gene therapy is to deliver the corrective gene to
the airway epithelium to restore chloride channel activity.
However, several gene therapy trials with vectors including
adenovirus (Ad), adeno-associated virus (AAV) and liposomes did
not achieve clinically relevant levels of CFTR gene transfer [7,8].
In addition, the administration of adenoviral vectors [9,10] and
AAV [11,12] augmented inflammation, due to the presence of
neutralizing antibodies and T cell responses in the already-
compromised respiratory system. The aerosol administration to
the lungs of a cationic liposome, GL67, complexed with plasmid
DNA caused febrile flu-like symptoms in some patients [13,14].
We have shown previously that a novel nanocomplex for-
mulation was effective at delivering genes to the lungs of mice by
direct instillation [15]. These receptor-targeted nanocomplexes
(RTNs) comprised peptides (K16GACSERSMNFCG), cationic
liposomes (DHDTMA/DOPE) and plasmid DNA. The peptide
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proteins of two intracellular pathogens, rhinovirus and Listeria
monocytogenes [16]. Rhinoviruses of the major group bind
intercellular adhesion molecule-1 (ICAM-1, CD54) [17], which
is upregulated in chronically inflamed airway epithelium [18,19],
hence suggesting it could be an appropriate receptor target for CF
vectors.
Nebulisers are used extensively for the administration of
medication by inhalation, typically generating aerosol particles
less than 5 mm in diameter that can reach the lower respiratory
tract. Thus nebulisation is an attractive option to deliver genes
directly to the affected epithelial cells in the lungs of patients with
CF. A crucial step towards this goal is to find an appropriate
formulation and a compatible nebuliser. Vector suspensions should
maintain their stability and biophysical characteristics, protecting
the plasmid DNA from shearing forces during nebulisation so that
its biological activity is preserved. In addition, the yield from the
nebuliser must be maximised [20]. A careful evaluation of the
delivery device is therefore an essential requirement for designing a
CF gene therapy protocol. Different types of nebuliser technologies
are available commercially including jet, vibrating mesh and
ultrasonic nebulisers. In the present study we assessed the delivery
of RTN suspensions with jet and vibrating mesh nebulisers, as the
ultrasonic devices are not suitable for liposome-based vectors [21].
The aerodynamic particle sizes of RTN aerosols were
determined by sample deposition in a Next Generation Pharma-
ceutical Impactor (NGI). The stage at which the aerosol is
deposited in the seven-stage cascade impactor, reveals the terminal
settling velocity of the nebulised suspension dependent upon the
aerodynamic diameter (specific density, shape and gravity) of the
aerosolised particles [22].
RTN formulations in an AeroEclipse II BAN nebuliser
displayed particle stability following nebulisation and retained
transfection efficiency in vitro and in vivo, while aerosol aerody-
namic sizes were compatible with deposition in the airways and in
the lung. Therefore, RTN formulations delivered by an Aero-
Eclipse nebuliser showed the characteristics desirable for CF gene
therapy.
Results
Influence of the nebuliser on RTN delivery
Although convenient for administration of therapeutics to the
airways, the nebulisation process of transforming a liquid
medication into a respirable mist can involve strong shearing
forces, particularly in jet nebulisers. These devices are usually
operated until no more useful aerosol is generated, although in jet
nebulisers a residual volume of the suspension usually remains in
the sample reservoir. We examined the aerosolisation of the RTN
suspensions, based on the LED-1 formulation described previously
[15] comprising a cationic liposome (DHDTMA/DOPE), a
peptide E (K16GACSERSMNFCG) and a plasmid DNA using
different nebulisation systems and focused on their suitability for
treating CF patients. At the transfection weight ratio of 1.5:4:1
(L:P:D), the formulation contained, per plasmid, approximately
2,750 peptide molecules, 4,550 molecules of DHDTMA and 3,750
molecules of DOPE. The calculated N/P ratio was approximately
5, supporting the observation that the nanocomplexes were
positively charged.
Two jet nebulisers, the AeroEclipse II BAN and PARI-LC Plus,
which use rapidly expanding compressed air to atomise drug
solutions and suspensions, were compared with a vibrating mesh
nebuliser, the AeronebH Pro. The vibrating mesh nebuliser has the
potential advantage of lower shearing forces and a more efficient
aerosolisation process, with a negligible residual volume following
nebulisation. In comparison experiments, all the nebulisers were
operated for 10 min and the AeroEclipse was used in open vent
mode which allows for prolonged admission of gas through the
vent which results in shrinkage of the aerosol droplets due to
evaporation, increasing the nebuliser performance [20]. The
aerosolised nanocomplex suspension was collected from the NGI.
The air flow rate in the NGI was 15 L/min and the equipment
was chilled before each experiment to reduce evaporation of the
deposited material during the experimental procedure [23].
The average output efficiency of RTNs from the three different
nebulisers, compared by quantifying DNA in the nebuliser
chamber prior and after completion of the aerosolisation, was
approximately for the Aeroneb 43%, PARI 86% and AeroEclipse
85%, respectively (n=2). The transfecting activity of the aerosolised
nanocomplexes, collected from the different stages of the NGI, was
measured in normal bronchial epithelial (16HBE14o-) cells
(Figure 1A and Table 1) or CF bronchial epithelial (CFBE41o-)
cells (Figure 1B and Table 1), after diluting them with OptiMEM
serum-free medium. The b-galactosidase activity measured in cell
lysates transfected with samples from the different stages of the NGI
suggested that the Aeroneb generated smaller aerosol droplets than
the other two nebulisers, with most activity recovered from stage 7
(particles with an aerodynamic diameter of less than 0.98 mm) and
the micro-orifice collector (S8), while in CFBE14o- cells expression
wasalsofoundinstages6–8,withpeakactivityinstage7 (Figure1A,
1B and Table 1). The pattern of nanocomplex distribution was
comparable for both the AeroEclipse and PARI jet nebulisers,
where the vast majority of the transfection activity was found in the
aerosol particles deposited between stages 2 to 6 representing
aerodynamic diameters of 8.6 mm to 1.4 mm, respectively.
Samples from the Aeroneb showed no difference in either the
sizes (160 nm) or the f (electrokinetic or zeta) potentials (+46 mV)
between the post-nebulisation residual material in the nebuliser
reservoir (LO) and the suspension prior to nebulisation (PN)
(Figure 1C). However, the RTNs nebulised with the PARI-LC
Plus were larger post-nebulisation (210 nm) than pre-nebulisation
(158 nm) with the f potential decreased from +46 mV to +39 mV
(Figure 1C). RTNs collected from the AeroEclipse post-aerosol
and the leftover in the nebuliser chamber (Figure 1C, last two bars
and diamonds), showed a slight decrease in the geometric sizes
(144 nm and 126 nm, respectively) and a slight increase in the f
potential (+48 mV and +53 mV, respectively).
To further compare the AeronebH Pro and the AeroEclipse II
BAN, an in vivo study, with nine mice per cohort, was performed
by whole-body nebulisation with a 2 ml single dose of RTNs
containing the luciferase reporter gene plasmid pCILuc at a
concentration of 160 mg/ml of pDNA. Luciferase assays of lung
extracts (n=7/group) at 24 h after aerosolisation indicated that
the AeroEclipse was the most efficient nebuliser for in vivo delivery
to mice (Figure 1D). Indeed, 71% of the C57BL6 mice (5/7)
showed luciferase expression in their lungs, versus 29% (2/7) of
those aerosolised with the Aeroneb (one of which was positive at
very low level). Values of luciferase activity (Relative Light Unit)
from the lungs of mice nebulised with the AeroEclipse were
statistically different at 0.05 level, compared to those aerosolised
with the Aeroneb, however when normalised to the protein
concentration there was no difference between the two groups.
Lungs from the two remaining mice were used for immunohis-
tochemical localisation of luciferase. Luciferase enzyme was
detected predominantly in ciliated tracheal epithelial cells
following nebulisation with the AeroEclipse (Figure 1F). No
positive staining was observed in the lower airways or parenchyma
of either mouse. No staining was observed in sections from naı ¨ve
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with the primary antibody was omitted (Figure 1E).
In summary, the RTN formulations nebulised with the
AeroEclipse II BAN, preserved almost unchanged the parameters
of the colloidal suspension and was the most effective nebuliser in
vivo and therefore was used for further investigations. The
AeronebH Pro, distributed to later stages of the NGI (particles
with an aerodynamic diameter less than 2 mm) and presumably
would deposit aerosol deeper in the lung in vivo. It also tended to
block during nebulisation making its use problematic. The
nanocomplexes nebulised through this device remained intact by
particle size measurements thus indicating a preserved activity, but
its efficacy in vivo was not as good as the AeroEclipse. The PARI-
LC Plus showed some alterations in the physical properties of the
suspension nebulised and so was not investigated further.
Yield of DNA from nebulised nanocomplexes
To better characterise the RTN suspension nebulised by the
AeroEclipse, DNA degradation and/or particle disruption was
then assessed. RTN suspension (3 ml) was nebulised into the NGI
and samples were collected from the different stages by rinsing
each cup and the throat with 1 ml of water. DNA was released
from the nebulised nanocomplexes and non-nebulised suspensions
by detergent treatment, then analysed by agarose gel electropho-
resis and the DNA was quantified by densitometry. The amount of
DNA recovered was higher from stages 3–5 (aerodynamic
diameter of 5.4 – 2.1 mm, respectively), though stage 6 (1.4 mm)
showed some positivity (Figure 2A). The packaging of DNA in the
suspension of liposomes and peptides appeared to protect the
DNA from breakage. In a few experiments we noticed a slight
increase in the amount of nicked/relaxed circles, but this could
have arisen during the sample processing.
Quantification of the plasmid DNA bands by densitometry,
expressed as a percentage of the total (PN), indicated that the yield
of nebulised nanocomplexes obtained from the NGI was 63% of
DNA (Figure 2A). The vast majority of the DNA was found in
stages 2–6 (8.6 mm – 1.4 mm), accounting for about 45% of the
total DNA nebulised and approximately 70% of that recovered
after nebulisation.
The distribution of quantified DNA from two independent
experiments (Figure 2B) followed essentially the same pattern of a
single experiment shown in the gel in figure 2A. The yield of DNA
collected from the NGI compared to the starting material on
average was around 77%, for the nanocomplexes, at a DNA
concentration of 160 mg/ml, formulated in H2O.
The physical size and stability of the nebulised
nanocomplexes collected from the NGI
The average geometric size of the nanocomplexes from the
aerosol collected in the NGI cups was compared to pre-nebulised
samples to further determine the stability of the nanocomplexes to
nebulisation. In this experiment the nanocomplexes increased in
size after nebulisation, from 150 nm to about 200–230 nm
(Figure 3), suggesting that the increase of the size may have
occurred during the passage of the aerosolised suspension through
the NGI. The f potential also increased from +45 mV to +54–
56 mV indicating that the nanocomplexes bearing a higher
colloidal stability were preferentially aerosolised.
Quantification of the cells transfected
The samples retrieved from the different stages of the NGI were
also used to determine their post-nebulisation ability to transfect
cells, using the enhanced green fluorescent protein (EGFP)
reporter gene. Equal volumes of nebulised material were added
to cultures of normal (16HBE14o-) or CF (CFBE41o-) bronchial
epithelial cells to detect the EGFP expression by flow cytometry.
The viable cells were selected by staining with propidium iodide as
shown in the control panel. The percentages of live EGFP-
transfected cells at each stage of the NGI are shown in comparison
with the EGFP-negative population. Pre-nebulisation suspension
(PN) and nanocomplexes remaining in the nebulisation chamber
upon completion of the nebulisation (LO) transfected the highest
number of cells, while fewer positive cells were found in trans-
fections performed with material collected from the throat and
stages 1, 7 and 8. The number of cells transfected seemed to
display a normal distribution trend from stage 2 (aerodynamic
diameter of 8.6 mm) to stage 6 (1.4 mm), having its maximum
peak at stage 4 (aerodynamic diameter cut-off of 3.3 mm). Flow
cytometry profiles of 16HBE14o- cells transfected with pEGFP
(Figure 4) clearly demonstrated that the distribution of EGFP-
positive cells transfected with nanocomplexes recovered from the
Figure 1. Comparison of vector delivery with three nebulisers (AeroEclipse II BAN, PARI-LC Plus and AeronebH Pro). A and B
Transfections of 16HBE14o- and CFBE41o- cells mediated by RTNs nebulised through the NGI: RTNs were made in clinical grade H2Oa t
weight ratio of 1.5:4:1 of DHDTMA/DOPE (1:1 molar ratio), peptide E and pCpG-free lacZ plasmid DNA, respectively. 3 ml of RTN suspension was used
for each nebulisation and all three nebulisers were operated at a flow rate of 15 L/min for 10 min. After aerosolisation nebulised nanocomplexes,
deposited in the different stages of the NGI, were collected by adding to each stage 1 ml of water. A volume of the collected samples, diluted in
OptiMEM, was added onto cells. The expression of the reporter gene was assessed 48 h after delivery. Representative results of transfection
experiments in both cell lines for each nebuliser (AeroEclipse II BAN, PARI-LC Plus and AeronebH Pro) are shown. The error bars represent the
standard error of the mean of quadruplicate wells. Nebulisations through the NGI were repeated 3 times with each nebuliser for both cell lines and
cumulative results are reported in Table 1. RLU=Relative Light Unit; Thr=throat; S1–S8=stages 1–8 of the NGI, S8=micro-orifice collector. C
Physicochemical properties pre- and post-nebulisation: The size and the f (electrokinetic or zeta) potential were measured using a Malvern
Nano ZS Zetasizer on aliquots of pre-nebulised nanocomplexes, of nebulised samples collected in a 50 ml tube, and of residual RTN suspension
remaining in the nebuliser chamber upon completion of the nebulisation. The average values of three independent measurements of each sample
were automatically performed. Bars represent the average values of the sizes of two independent experiments 6 the standard deviation whereas the
diamonds indicate the f potentials in the same samples 6 the standard deviation. PN=pre-nebulisation RTN suspension; post=post-nebulised
nanocomplex suspension; LO=(leftover) RTNs retained in the nebuliser chamber. D In vivo delivery of RTNs containing luciferase reporter
gene in C57BL6 mice: 2 ml of RTNs, prepared with pCILuc plasmid, were nebulised using either the AeronebH Pro or the AeroEclipse II BAN, into a
Plexiglas chamber in which 9 mice (C57BL6 strain) were confined. 24 h later, 7 of the murine lungs were then analysed for luciferase expression as
described in the methods. Luciferase activity is expressed as Relative light Unit (RLU) per milligram of protein. There was not statistical difference
between the two groups when the readings were normalised to protein content, but there was a statistical difference (p,0.05) in the luciferase
activity (Mann-Whitney test). E and F Localisation of luciferase expression by immunohistochemistry: Trachea of C57BL6, following a single
nebulisation of 2 ml of RTNs containing pCILuc were stained with 3,39-diaminobenzadine (F), and counterstained with haematoxylin. The transfected
tissue was localised in the ciliated airway epithelium whereas the negative control section (E) was not probed with the primary antibody. Objective
magnification: 406.
doi:10.1371/journal.pone.0026768.g001
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the amount of DNA recovered (Figure 2). Similar results were
obtained for the same experiment repeated in 16HBE14o- cells
and in two independent experiments in CFBE41o- cells (Table 2).
Gene expression from nebulised delivery to mice
The reporter gene for b-galactosidase regulated by an EF1a
promoter was selected for reporter gene studies in vivo to minimize
the immune response to hypomethylated CpG repeats found in
most plasmid DNA. In addition, the EF1a promoter was shown
previously to confer more persistent expression in vivo [24,25].
Groups of six CD1 mice were subjected to whole body
nebulisation with RTN suspensions at 160 mg/ml pCpG-free lacZ
DNA. Mice were killed after 48 h then lung and trachea samples
were analysed for b-galactosidase expression by the CPRG assay
(Figures 5A and B, respectively), or by b-galactosidase immuno-
detection on dot blots (Figures 5C and D) in tissue lysates.
The enzymatic activity measured in the lungs (Figure 5A) was
not statistically different between the treated (nebulised with
RTNs) and the control group (nebulised with water). However, in
the tracheas (Figure 5B) the difference between the control and the
cohort nebulised with the reporter gene was statistically significant
(p,0.05). In all the experiments high levels of endogenous b-
galactosidase activity was found in the controls, consistent with
previous reports [26,27,28]. In the lungs, the quantification of the
b-galactosidase protein (Figure 5C) showed a more substantial
difference than the enzymatic activity. The results in the tracheas
appeared consistent between the two different assays (Figures 5B
and D).
Discussion
Despite the many therapies in the pipeline targeting specific
defects in CFTR transcription and expression or modulation of the
channel functions [8], there is still a clinical need for gene therapy-
based treatment for cystic fibrosis [29]. In the current study, we
aimed to optimise the previously developed molecular conjugates
for in vivo delivery via aerosolisation. We have described previously
the RTN formulation, a modular, self-assembling receptor-
targeted nanocomplex (RTN) formulation comprising a mixture
of cationic liposomes, a receptor-targeting/DNA-binding peptide
and plasmid DNA (D). This formulation displayed receptor-
targeted transfection mediated by the peptide, with endosomal
release of DNA to the cytoplasm enhanced by the liposome
component [30]. In developing the RTN formulation for gene
therapy of cystic fibrosis we have demonstrated its capacity to
transfect non-dividing epithelial cells in vitro [31], and optimised
the lipid and peptide components of the formulation for gene
delivery to airway epithelial cells [16,32]. In vivo studies performed
in rats [33], mice [15,34] and pigs [35] demonstrated high
efficiency of transfection in airway epithelium combined with low
inflammatory potential.
The RTN formulation used in this study is the same as that
delivered to mice in recent studies by intratracheal instillation [15].
The peptide contains the targeting motif SERSMNF, an epithelial
targeting peptide identified by our group in phage display
biopanning experiments [16]. SERSMNF is almost identical to
the ICAM-1 targeting sequence of rhinovirus a respiratory
pathogen. The K16 region of the peptide is important for DNA
packaging. The lipid component is DHDTMA/DOPE where
DHDTMA is a cationic lipid based on a glycerol backbone with
two unsaturated C16 alkyl chains linked by diether linkages [32].
RTN particles target cells by both ICAM-1 receptor and by non-
specific cationic properties, and are internalised endocytically. The
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26768Figure 2. Analysis of the DNA recovered from nanocomplexes collected from the NGI stages. A Visualisation of bands on agarose
gel: After nebulisation of RTNs through the NGI with the AeroEclipse, the DNA (pEGFP-N1 plasmid) was released from samples collected from each
stage, the throat (Thr), as well as the suspension pre-nebulisation (PN) and the leftover (LO) in the nebuliser reservoir. The released DNA was
electrophoresed on agarose gel, alongside the original plasmid used to form the complexes (ctrl), and visualised by EtBr staining under UV light. A
representative experiment is shown. The total yield of DNA of the experiment shown was 63% and the yield relative to each band of DNA in the gel is
also indicated underneath. B Quantification of bands of DNA released from the RTNs: Nanocomplexes prepared at the DNA concentration of
160 mg/ml were nebulised through the NGI and the RTNs pre-nebulisation (PN), the leftover in the nebulisation chamber (LO) or deposited in the throat
(Thr) or in the various stages (S1–S8) were collected. The DNA extracted from the samples was analysed by agarose gel electrophoresis. The agarose gel
images acquired were analysed by ImageJ. To compare the density values per area, the region of interest (ROI) of each independent experiment was
normalisedto1,beforecalculatingthemean values.Theexperiments wereperformedtwiceandtheerrorbars representthestandarderrorofthemean.
doi:10.1371/journal.pone.0026768.g002
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PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26768lipid component mediates endosomal release of the DNA, which is
subsequently transported to the nucleus. This step may be
facilitated by the K16 peptide domain interacting with nuclear
importins. Thus there is a high degree of synergy between the lipid
and peptide components that contribute to its transfection
efficiency.
Aerosol therapy, with mucolytics, antibiotics and other
treatments, is widely used to treat CF patients and would be the
best option for gene therapy interventions. Different nebulisers
were compared to determine if their mode of operation resulted in
delivery of RTNs likely to reach the lower airways whilst retaining
their transfection efficiency.
Three nebulisers were selected for comparison. The AeronebH
Pro was tested as it has been shown to generate aerosol particles
appropriate for delivery to the lower respiratory tract and it has
the added advantage of yield efficiency, due to the vibrating mesh
design. Unfortunately, in these experiments, RTN delivery
efficiency of the AeronebH Pro was significantly less than that of
the two jet nebulisers. The pores in the mesh appeared to block
during nebulisation. The reason for this is unclear, but may be
related to the high positive charge of the RTNs adhering to the
mesh. The PARI-LC Plus is a commonly used breath-enhanced
nebuliser that has an advantage over conventional jet nebulisers in
that the amount of suspension delivered during inspiration is
greater. This is achieved through a valve on the top of the
nebuliser opening due to the negative pressure developed by the
patient during inspiration pulling more air through the nebuliser
and with it more aerosol particles. On expiration, the valve closes
and during this time the nanocomplex suspension is lost from the
device in a similar amount to that of a standard jet nebuliser. The
AeroEclipse II BAN is a newly designed nebuliser that only
nebulises during inspiration when the negative pressure pulls a
central ‘column’ down that enhances the Bernoulli effect of the
rapidly expanding gas from the compressor. This results in fluid
being pulled up from the reservoir for nebulisation only during
inspiration. Unlike the PARI-LC Plus no nanocomplex suspension
is lost during expiration from the AeroEclipse resulting in more
RTNs being available for inhalation. The option of operation in
breath-actuated mode would be extremely useful in the clinical
setting as the aerosol is produced in response to the patient
inspiration rate.
As both nebulisers otherwise produced aerosolised nanocom-
plexes that retained their transfection properties the AeroEclipse II
BAN was chosen for the remaining experiments. The AeroEclipse
nebuliser was examined in more detail for DNA degradation or
particle disruption during the aerosolisation process, for biophys-
ical properties, for the ability of transfecting a sufficient number of
cells to be clinically relevant and for its efficacy in a small animal
model.
The nebulised nanocomplexes not only retained the ability to
transfect, but the integrity of their DNA content was also
preserved (Figure 2) in agreement with what was previously
reported by others [36,37]. Those RTNs showed enhanced
colloidal stability (Figure 3), therefore were less prone to
aggregation or flocculation.
Several reports indicate that as little as 6–25% of epithelial cells
with restored CFTR functions are sufficient to correct the disease
[38,39,40]. The result in figure 4 not only quantified the number
of cells transfected by nanocomplexes, but provided also a good
indication at which level of the airways the gene expression could
be expected. The NGI data predicted that the majority of cells that
are likely to receive the reporter gene resided in the central
(trachea) and lower ciliated thoracic portion of the respiratory tree,
and not in the alveoli or in the upper airways.
The AeroEclipse aerosolised RTNs demonstrated productive
gene expression in most of the C57BL6 mice lungs and luciferase
expression was found in ciliated cells in immunohistochemical
sections of the trachea. In vivo experiments in another murine
strain, CD1 mice, confirmed that the delivery of the gene occurred
both in the trachea and in the lungs and demonstrated that the
delivery and the expression are not strain related. The CD1 mice
are a bigger strain than the C57BL6, and were able to reach easily
the nozzle, thus were more effective at breathing in the aerosol. No
changes were observed in the breathing pattern of either strain
during nebulisation. Apoptotic activity of the RTNs on the
epithelium as well as the inflammation associated to pCILuc was
assessed in a previous study [15]. It has been previously reported
that plasmids devoid of unmethylathed CG dinucleotides (CpG)
were less inflammatory [41].
We used pCpG-free lacZ plasmid-based RTNs to nebulise CD1
mice and the expression of the reporter gene was measured with
different methods in both lungs and tracheas. Although similar
trend was shown in both tissues, the enzymatic activity in the lungs
of treated animals was not statistically different when compared to
the controls. The interpretation of the data was complicated
because b-galactosidase activity is more difficult to detect in lung
tissue than in other tissue types, especially with low gene
expression levels [42]. Although the lacZ reporter gene delivered
is derived from Escherichia coli, mammalian tissues also express
endogenous b-galactosidase or enzymes with similar catalytic
(metabolic) activity, which determines high background level
[28,43,44]. A further hurdle is due to the presence of blood in
tissues, which interferes with the read-out of several colorimetric
substrates as the haemoglobin has a broad spectrum of absorption
[44]. To minimise the potential misinterpretation of the results
(Figure 5) when measuring the enzymatic activity, we used chloro-
phenol-red-b-D-galactopyranoside (CPRG) as substrate, which is
more sensitive and accurate [43], and to detect the protein (dot
blots) we probed the tissue lysates with an antibody specific for the
bacterial b-galactosidase.
Figure 3. Geometric diameters and electrokinetic potentials (f)
of RTNs before and after nebulisation through the NGI. The
aliquots of the same samples nebulised through the NGI (as in
Figure 2A) were used to measure the size (bars) and the f potential
(diamonds) using the Malvern Nano ZS Zetasizer. The average values of
three independent measurements per each sample were automatically
performed. Results of two independent experiments 6 the standard
deviation, from samples providing accurate readings are shown:
PN=pre-nebulisation RTN suspension; LO=(leftover) RTNs retained in
the nebuliser chamber upon completion of the nebulisation and
samples from stages 3–6 of the NGI.
doi:10.1371/journal.pone.0026768.g003
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26768In this study we have demonstrated that RTN formulations in
water can be nebulised with optimal efficiency levels by
AeroEclipse II BAN jet nebuliser. The nebulised aerosol
containing the nanocomplexes was collected in the cups of a
NGI and showed to have an aerodynamic size in the range of
approximately 2–8 mm. Aerosol particles of this size would be
compatible with deposition in the upper part of the lower
respiratory tract rather than deeper in the lung, which correlates
with the region of highest CFTR expression in the lung and so is
the required target site for delivery of CF gene therapy [45].
Nebulised nanocomplexes retained their biophysical properties,
and pDNA extracted from the nanocomplexes was present as
intact circular molecules. In vitro transfection experiments
demonstrated that the nebulised nanocomplexes and pDNA
retained their functionality for gene expression in transfected
cultures of bronchial epithelial cells. In vivo delivery of RTNs by
whole body nebulisation with the AeroEclipse II BAN nebuliser,
led to the successful transfection of murine lungs, which was
particularly evident in ciliated cells of the upper airways. Further
studies are needed to assess the delivery of the corrective gene in
vivo, and efficacy after repeated dosing.
Our findings may foster new opportunities for the therapeutic
intervention of cystic fibrosis. The dynamic airway plasticity
requires repeated applications and the receptor-targeted nano-
complexes presented in the current work may offer an advantage
for clinical translation.
Materials and Methods
RTN formulation
Receptor-targeted nanocomplexes (RTN) were prepared as
described elsewhere [15]. Briefly, liposomes formulated with
Figure 4. Transfection efficiencies mediated by RTNs carrying pEGFP plasmid and assessed by flow cytometry. RTNs were formed
using pEGFP-N1 plasmid DNA. Aliquots of nanocomplexes nebulised through the NGI (as in Figure 2A and 3) were used to perform transfections.
After 48 h incubation, cells were harvested and analysed by flow cytometry to determine the level of expression of enhanced green fluorescent
protein (EGFP) in the samples collected from each NGI stage. A representative experiment carried out in normal human bronchial epithelial cell-line
16HBE14o- is shown (cumulative experiments are summarised in Table 2). The dot-plot profile of untransfected cells (ctrl) represents the population
selected as alive whereas the 1st panel of histogram profile shows where the markers to discriminate the EGFP positive from negative population
were set. On each panel the percentage of EGFP negative (left) and EGFP positive (right) cells is indicated. PN=represent cells transfected with pre-
nebulisation RTN suspension; LO=cells treated with leftover nanocomplexes in the nebuliser chamber after nebulisation, Thr=throat, and S1–S8 cells
transfected with samples from the different NGI stages, respectively.
doi:10.1371/journal.pone.0026768.g004
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SERSMNFCG) and plasmid DNA, all dissolved in water (Baxter
S.A., Lessines, Belgium), at the weight ratio of 1.5:4:1 (L:P:D).
Complexes were then left to assemble for at least 1 h at room
temperature before being used either for transfections or for
nebulisation experiments.
DHDTMA chloride [1-propanaminium, N,N,N-trimethyl-2,3-
bis(11Z)-hexadecenyloxy)-chloride) [46] and DOPE (1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine), liposomes were prepared at
1:1 molar ratio as described previously [32], or purchased from
Avanti Polar Lipids Inc. (Alabaster, AL, USA). Peptide E was
synthesised by Zinsser Analytic (Maidenhead, UK). Plasmid DNA
encoding for enhanced green fluorescent protein (pEGFP-N1) was
from Clontech (Clontech-Takara Bio Europe, Saint-Germain-en-
Laye, France), whereas plasmid pCILuc consists of pCI (Promega,
Southampton, UK) carrying a luciferase gene driven by the CMV
promoter-enhancer [16]. The pCpG-free lacZ plasmid (Invivogen,
San Diego, CA, USA) encodes for b-galactosidase under the EF1a
promoter, but is devoid of CpG dinucleotides.
Cell transfections
The normal bronchial (16HBE14o-) and the CF (CFBE41o-)
cell-line, kindly provided by Dieter Gruenert (California Pacific
Medical Center Research Institute, San Francisco, CA, USA),
were maintained in Minimum Essential Medium Eagle’s modifi-
cation (Sigma, Poole, UK) at 37uC in a humidified atmosphere
with 5% CO2. Tissue culture medium was supplemented with
10% heat-inactivated foetal bovine serum (FBS, Invitrogen,
Paisley, UK), 2 mM L-glutamine (Invitrogen) and 0.1 mM non-
essential amino acids (Sigma).
LacZ expression was measured in cell extracts with a b-glo assay
(Promega Corporation Madison, WI, USA) using a FLUOstar
Optima luminometer (BMG Labtech, Aylesbury, UK), according
to the instructions of the manufacturer. The results were
standardised for protein content using a Bradford protein assay
(Bio-Rad Laboratories, Hercules, CA, USA). Luminescence was
expressed as relative light units (RLU) per milligram of protein.
Nebulisations and Next Pharmaceutical Generation
Impactor (NGI)
The nebuliser AeroEclipse II BAN was a kind gift of Trudell
Medical International Europe Ltd (Manchester, UK), PARI-LC
Plus was purchased from PARI Medical Ltd (West Byfleet,
UK), while AeronebH Pro was kindly provided by Aerogen Ltd
(Galway, Ireland). For the nebulisation studies, 3 ml of nano-
complexes (unless stated otherwise), prepared in H2O, were
added to the sample chamber of the device. The nebuliser was
then connected to the compressor and to the throat of the NGI
(Copley Scientific Ltd, Nottingham, UK). The nebulisation was
performed for 10 min. The NGI was operated at a flow rate of
15 L/min, after cooling at 4uC for at least 1 h. The AeroEclipse
was set on continuous operational mode, thus providing a near
constant delivery rate independent from respiratory activity.
After nebulisation, the residual amount of nanocomplex suspen-
sion was measured and collected. All the NGI stages and
the throat were carefully rinsed with 1 ml of clinical grade H2O
(Baxter). Aliquots of the recovered material were used for
cell transfections, particle sizing and for DNA quantification
experiments.
Flow cytometry
RTN formulations containing the pEGFP-N1 plasmid (Clon-
tech-Takara Bio Europe) were nebulised through the NGI.
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PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e26768Pre-nebulisation samples (PN), the leftover (LO) in the nebuliser
reservoir upon completion of the nebulisation and the aerosolised
samples, collected from the throat and the different stages of the
NGI and diluted with 1 ml of clinical grade H2O, were used for
transfections. 30 ml of each sample was added to 500 ml OptiMEM
(Invitrogen) and then to cells seeded in 24-well plates, grown at
80% confluence. After 48 h incubation, the cells were trypsinised
and filtered with a cell strainer (Ø 70 mm). Cells of duplicate wells
were pooled together in PBS containing 3% FBS, before analysing
EGFP expression by flow cytometry (LSRII, DB Bioscience
Europe, Oxford, UK). Cell viability was determined by propidium
iodide staining (Sigma) and at least 10,000 live cells were acquired.
Quantification of DNA released on agarose gel
RTN formulations were nebulised as described above. All the
samples pre- and post-nebulisation, and from the different NGI
stages were collected. The DNA was released from the
nanocomplexes as described previously [47]. Briefly, 100 mlo f
Figure 5. In vivo transfection efficiency after a single dose nebulisation in CD1 mice. RTN suspension (6 ml), at a concentration of 160 mg/
ml of DNA, was nebulised using the AeroEclipse II BAN in a plexiglass box containing 6 CD1 mice. After 48 h following the nebulisation, the animals
were culled and the lungs and the tracheas removed. In the harvested tissues, the levels of b-galactosidase were measured by quantifying the
enzymatic activity and by immunodetecting the protein. Control animals were nebulised with the same clinical grade H2O in which nanocomplexes
were made. A and B Determination of b-galactosidase enzymatic activity: The b-galactosidase activity was measured by CPRG assay in both
whole lung lysates (A) and in those from the tracheas (B). The activity of enzyme (mU) in the lysates was calculated against the b-galactosidase
activity of Escherichia coli and normalised for the total protein content. (*) in panel B (tracheas) indicates statistically significant difference (Mann-
Whitney test) at 0.05 level (p,0.05). No difference was found in panel A, although there the protein activity showed a similar trend. C and D
Detection of b-galactosidase protein: The lysates from the whole lungs (C) and the trachea (D) from each mouse were spotted onto PVDF
membranes. Dot blots were first probed with goat polyclonal anti-b-galactosidase antibody and then with horseradish peroxidase-labelled rabbit
polyclonal anti-goat immunoglobulin. The quantification of duplicate dots per each mouse is shown. The difference between the control group
(nebulised with water) and the cohort which received RTNs formed using pCpG-free lacZ reporter gene, was statistically significant at the Mann-
Whitney test (*, p,0.05).
doi:10.1371/journal.pone.0026768.g005
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buffer (20 mM Tris-Cl, pH 8.0, 200 mM NaCl, 50 mM EDTA
and 1% SDS) and incubated at 50uC for 35 min. The DNA was
then purified with the WizardH DNA Clean-Up System (Promega)
according to the instructions of the manufacturer. 25 ml of each
sample was loaded and run onto 1% agarose gel. The gels were
visualised under UV light and the images were used for DNA
quantification. The band densities, following the rolling ball
background subtraction set at 20, were analysed on ImageJ
programme (http://www.NIH.gov) and the yield of the recovered
DNA was calculated.
The yield was expressed as percentage of the sum of the density
of DNA (r) in each lane corrected for the volume of the sample
collected (V), divided by the density of DNA of the starting
nanocomplex suspension (rPreNeb) also corrected by the volume
(VPreNeb).
yield(%)~
P
½(rLO|VLO)z(rThr|VThr)z(rS1|VS1)z::::::z(rS8|VS8) 
(rPreNeb|VPreNeb)
|100
Size and f potential of the RTN complexes
RTN complexes, freshly prepared by using 160 mg/ml of either
pCILuc or pCpG-free lacZ plasmid, or the samples collected from
the NGI cups were diluted 100-fold in DNAse- and RNAse-free
water (Invitrogen) to a final volume of 500 ml.
Nanocomplex sizes and f potentials were determined by
dynamic light scattering and by laser Doppler anemometry,
respectively, using a Nano ZS Zetasizer (Malvern Instruments,
Malvern, UK) with the following specifications: automatic
sampling time of 10 measurements/sample, refractive index of
1.330, dielectric constant 78.5, viscosity 0.8872 cP and temper-
ature of 25uC. f potential settings were calibrated against the
standard (268 mV66.8 mV). A total of three measurements per
each sample were automatically performed.
In vivo nebulisation
All animals were handled in strict accordance with good animal
practice as defined by the UK Home Office Animal Welfare
Legislation, and all animal work was approved by the Institutional
Research Ethics Committee (Institute of Child Health, University
College London, UK) and performed under Home Office project
license number 70/7073.
To determine the effectiveness of the different nebulisers, 2
cohorts of 9 female mice of C57BL6 strain (Charles River, UK),
were restrained in the Plexiglas box, with 2 apertures, one of which
was connected to the nebuliser, while in the second outlet a filter
was installed. Once acclimatised, the mice were nebulised with
2 ml of RTN suspension, containing 160 mg/ml pCILuc DNA,
over maximum 30 min. The aim of this procedure was to allow
comparison of in vivo delivery with the AeroEclipse II BAN and
AeronebH Pro. All the nebulisers produced an aerosol mist, which
filled the air within the cage, though the AeronebH Pro blocked
frequently. Mice were sacrificed at 24 h, the lungs were perfused,
resected and 7 were stored at 280uC, while 2 were fixed for
immunohistochemistry. Tissues were defrosted in ice, submerged
in reporter gene assay lysis buffer (RLB, Roche, Basel, Switzer-
land), homogenised with an IKA homogeniser (IKA, Staufen,
Germany) and centrifuged at 18,8906g for 10 min at 4uC. The
supernatants were removed and centrifuged at 18,8906 g for a
further 10 min at 4uC before measuring the luciferase activity.
To assess the vector delivery using pCpG-free lacZ reporter
gene, CD-1 female mice of 6–8 weeks of age (Charles River, UK),
weighing 28–30 g, were confined in the same Plexiglas box
mentioned above. The AeroEclipse nebuliser was filled with 6 ml
of RTN suspension and set on continuous operational mode. All
animals were exposed to the aerosol mist containing pCpG-free
lacZ DNA at a concentration of 160 mg/ml, or H2O as control, for
about 30 min, respectively. 48 h after nebulisation, all the 6
animals of each cohort were sacrificed. The lungs and tracheas
were collected and stored at 280uC. Tissues were then defrosted
on ice, added into RLB (Roche), subjected to hard tissue
homogenisation with Precellys 24 (Bertin Technologies, France)
and centrifuged at 18,8906g for 3 min at 4uC. The supernatant
was collected and centrifuged at 18,8906g for 10 min at 4uC. The
samples were then stored at 220uC before biochemical analysis
for the expression of b-galactosidase.
Luciferase activity detection
Luciferase activity in the tissue lysates was measured over 30 s
using the Luciferase Assay System (Promega) in a FLUOstar
Optima luminometer (BMG Labtech). The amount of protein
present in each transfection lysate was determined with the Bio-
Rad protein assay reagent (Bio-Rad Laboratories). Luciferase
activity was expressed as relative light units (RLU) per milligram of
protein. Two million RLU/30 s corresponds to 1 ng of luciferase.
Two of C57BL6 mice nebulised with 2 ml of RTN formulations
containing pCILuc were used for luciferase immunohistochemis-
try. After killing, the lungs and tracheas were fixed in 4%
paraformaldehyde. Sections were analysed for firefly luciferase
expression, 5 mm thick sections were dewaxed, rehydrated, and
blocked with hydrogen peroxide and normal rabbit serum and
then processed as described previously [34].
Biochemical measurement of b-galactosidase activity
The b-galactosidase enzymatic activity was assessed by CPRG
(chloro-phenol-red-b-D-galactopyranoside) assay [48,49]. 50 mlo f
tissue lysate was added to 150 ml of 1 mg/ml CPRG solution
(60 mM NaH2PO4, 1 mM MgSO4, 10 mM KCl, 50 mM b-
mercaptoethanol). The b-galactosidase standard curve was
prepared with a 2-fold dilution of b-galactosidase enzyme (Sigma)
in 100 mM phosphate buffer, pH 7.3, 10 mM MgCl2, and
10 mM b-mercaptoethanol, starting from 100 mU. The 96-well
plates were incubated at 37uC to allow the development of the
colour, before stopping the reaction with 50 ml of 1 M NaCO3.
The absorbance was read at 595 nm. The enzymatic activity was
normalised to total protein concentration as described above.
For the dot blot assay, 5 ml of samples (in duplicate) were
added to PVDF membrane (Ø45 mm, Immunobilon P, Millipore
UK Ltd. Watford, UK) and a further 25 ml of RLB (Roche) was
added. The vacuum was kept on for 1 h until the dots were
completely dried. The membrane was left overnight in PBS-1%
BSA, washed twice with PBS containing 0.05% Tween 20
(Sigma; PBS-Tw), then incubated for 90 min with goat polyclonal
anti-b-galactosidase antibody (10 mg/ml in PBS-Tw, AbD
Serotec, Kidlington, UK). After 3 washes with PBS-Tw, the dot
blot membrane was incubated overnight at 4uC with horseradish
peroxidase-labelled rabbit polyclonal anti-goat immunoglobulin
(50 ng/ml in PBS-Tw; Dako UK Ltd., Ely, UK). Following
further washing, the membrane was developed with ECL (Pierce,
Thermo Fisher Scientific - Rockford, IL, USA). Following the
rolling ball background subtraction set at 50, the densities of the
dots were analysed on ImageJ programme (http://www.NIH.
gov).
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Data were analysed using GraphPad 5.0 InStat (GraphPad
Software, Inc., La Jolla, CA) and are expressed as mean 6 SEM,
unless otherwise indicated. Population medians were interpreted
using a non-parametric (Mann-Whitney) test. Differences were
considered to be statistically significant for at least p,0.05.
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